Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA

Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma

(2018) David M. Kurtz et al.   JOURNAL OF CLINICAL ONCOLOGY

The value of liquid biopsy in diagnosis and monitoring of diffuse large b-cell lymphoma: recent developments and future potential

(2017) Vincent Camus et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma

(2017) Umberto Vitolo et al.   JOURNAL OF CLINICAL ONCOLOGY

Obinutuzumab for the First-Line Treatment of Follicular Lymphoma

(2017) Robert Marcus et al.   NEW ENGLAND JOURNAL OF MEDICINE

18F-FDG PET-CT and trephine biopsy assessment of bone marrow involvement in lymphoma

(2016) Chaitra S. Ujjani et al.   BRITISH JOURNAL OF HAEMATOLOGY

The Value of PET/CT in Detecting Bone Marrow Involvement in Patients With Follicular Lymphoma

(2016) Chava Perry et al.   MEDICINE

Opportunities and limitations of bone marrow biopsy and bone marrow FDG-PET in lymphoma

(2015) Hugo J.A. Adams et al.   BLOOD REVIEWS

Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial

(2014) S. Galimberti et al.   CLINICAL CANCER RESEARCH

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

(2014) Bruce D. Cheson et al.   JOURNAL OF CLINICAL ONCOLOGY

PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement

(2013) A. B. Khan et al.   BLOOD

Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program

(2013) M. Ladetto et al.   BLOOD

In Newly Diagnosed Diffuse Large B-Cell Lymphoma, Determination of Bone Marrow Involvement with 18F-FDG PET/CT Provides Better Diagnostic Performance and Prognostic Stratification Than Does Biopsy

(2013) L. Berthet et al.   JOURNAL OF NUCLEAR MEDICINE